ABCA9 , an ER cholesterol transporter, inhibits breast cancer cell proliferation via SREBP ‐2 signaling
Cancer Science · 2023-04 · 114 (4) · 1451-1463
DOI: 10.1111/cas.15710 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 18.01.2023. Verfasst von Hyeon-Ji Hwang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, BK21 Plus and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Ministry of Science and ICT and the National Research Foundation of Korea (NRF) SRC program: Comparative medicine Disease Research Center (CDRC).
Abstract (Originalsprache)
The association between cholesterol metabolism and cancer development and progression has been recently highlighted. However, the role and function of many cholesterol transporters remain largely unknown. Here, we focused on the ATP‐binding cassette subfamily A member 9 (ABCA9) transporter given that its expression is significantly downregulated in both canine mammary tumors and human breast cancers, which in breast cancer patients correlates with poor prognosis. We found that ABCA9 is mainly present in the endoplasmic reticulum (ER) and is responsible for promoting cholesterol accumulation in this structure. Accordingly, ABCA9 inhibited sterol‐regulatory element binding protein‐2 (SREBP‐2) translocation from the ER to the nucleus, a crucial step for cholesterol synthesis, resulting in the downregulation of cholesterol synthesis gene expression. ABCA9 expression in breast cancer cells attenuated cell proliferation and reduced their colony‐forming abilities. We identified ABCA9 expression to be regulated by Forkhead box O1 (FOXO1). Inhibition of PI3K induced enhanced ABCA9 expression through the activation of the PI3K–Akt–FOXO1 pathway in breast cancer cells. Altogether, our study suggests that ABCA9 functions as an ER cholesterol transporter that suppresses cholesterol synthesis via the inhibition of SREBP‐2 signaling and that its restoration halts breast cancer cell proliferation. Our findings provide novel insight into the vital role of ABCA9 in breast cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, BK21 Plus and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, Korea.
- Comparative Medicine Disease Research Center, Seoul National University, Seoul, Korea.
ORCID-Profile: Je-Yoel Cho
Förderung
- the Ministry of Science and ICT and the National Research Foundation of Korea (NRF) SRC program: Comparative medicine Disease Research Center (CDRC)
Zitieren
APA
Hwang, H. J., Lee, K. H., & Cho, J. Y. (2023). ABCA9 , an ER cholesterol transporter, inhibits breast cancer cell proliferation via SREBP ‐2 signaling. Cancer Science, 114(4), 1451-1463. https://doi.org/10.1111/cas.15710
Vancouver
Hwang HJ, Lee KH, Cho JY. ABCA9 , an ER cholesterol transporter, inhibits breast cancer cell proliferation via SREBP ‐2 signaling. Cancer Science. 2023;114(4):1451-1463. doi:10.1111/cas.15710
BibTeX
@article{Hwang2023,
author = {Hwang, Hyeon-Ji and Lee, Kang-Hoon and Cho, Je-Yoel},
title = {ABCA9 , an ER cholesterol transporter, inhibits breast cancer cell proliferation via SREBP ‐2 signaling},
journal = {Cancer Science},
year = {2023},
volume = {114},
number = {4},
pages = {1451--1463},
doi = {10.1111/cas.15710}
}
EUVIMED